What should I watch for next with Teva?
The most significant pending issue is the state generic price-fixing trial expected in Hartford in late 2026 — with Teva as lead defendant — plus the criminal deferred prosecution agreement running through 2028.
The most significant pending issue is the state attorneys general's generic price-fixing litigation, in which Teva is the lead defendant and which could go to trial in late 2026. Several co-defendants have already settled, including Sandoz, which agreed in August 2026 to pay about $469 million, and Apotex, Heritage, Lannett and Bausch.
A trial would put the states' evidence of an industry-wide conspiracy before a jury for the first time. Teva's payment schedule under the deferred prosecution agreement also continues, with a $135 million final instalment due in 2028.